1. Home
  2. Protocols and Guidelines
  3. Cancer Protocol Templates

Cancer Protocol Templates

Laboratories across the country and around the world rely on the CAP to help them stay current with the latest evidence-based practices and maintain quality and proficiency among the entire pathology team.

The CAP Cancer Protocols provide guidelines for collecting the essential data elements for complete reporting of malignant tumors and optimal patient care. These protocols incorporate the latest standards to help pathologists and laboratories keep abreast of the advances and updates in cancer reporting, including:

  • The World Health Organization Classification of Tumors (Blue Books)
  • The American Joint Committee on Cancer Staging Manual

Synoptic reporting using the CAP electronic Cancer Protocols (eCP) also helps laboratories and hospitals comply with requirements for organizations like the American College of Surgeons Commission on Cancer, the CAP Laboratory Accreditation Program, and more.

The CAP Biomarker Reporting Protocols are intended to provide reporting guidance for commonly ordered biomarkers and are not required for accreditation purposes.

Latest News and Resources

  • Open all Toggle
  • Close all Toggle

On March 19, 2025, the College of American Pathologists released updates to the CAP Cancer Protocols. The release has content changes to 9 protocols. Highlights of the Q1 release includes:  

  1. New Cancer Protocols: Paraganglioma Pheochromocytoma and PitNET  
  2. Breast Biomarker: Content and explanatory note updates to include modifications to ER testing, PgR and HER2 sections  
  3. Wilms Resection: Added International Society of Pediatric Oncology (SIOP) staging elements in addition to minor modifications of Children’s Oncology Group (COG) staging elements
  4. Invasive Melanoma Resection & Biopsy: Removal of pT staging elements from Melanoma biopsy.  Revision of Margins sections and updates to other content and explanatory notes in both the resection and biopsy protocols.
  5. Testis: Updated to accommodate partial orchiectomy specimens  

All changes are outlined in the March 2025 Summary of Revisions.

If you have questions or concerns, please email cancerprotocols@cap.org.

Current and previous cancer reporting and biomarker reporting protocols can be downloaded using the links in the table below.

On December 11, 2024, the College of American Pathologists released updates to the CAP Cancer Protocols. The release has content changes to 9 protocols. Highlights of the Q4 release includes:

  1. Cutaneous Head and Neck SCC: Updates to content and explanatory notes, including WHO Histologic Types. LVI question update from "Lymphovascular Invasion" to "Lymphatic and/or Vascular Invasion"
  2. Endometrium Uterus:
    • UPDATED Cover Page Instructions: Recommended for primary resection specimen with no residual cancer (e.g., following neoadjuvant therapy and / or following cancer diagnosis on previous biopsy / curettage)
    • Restored the FIGO 2009 Staging/2018 FIGO Cancer Report elements
    • Extensive updates to the case summary and explanatory notes
  3. Pharynx: AJCC Version 9 updates to Nasopharynx pTNM Classifications, associated content, and explanatory notes
  4. Urethra, Resection & Biopsy: Tumor Extent update
  5. Gynecologic Biomarker: Updates to HER2 testing and addition of subclonal loss of MMR expression, subclonal abnormal p53 expression, PD-L1 and folate receptor testing.
  6. AJCC Version 9 updates to content and explanatory notes to: Diffuse Pleural Mesothelioma, Lung Resection, and Thymus

All changes are outlined in the December 2024 Summary of Revisions.

If you have questions or concerns, please email CancerProtocols@cap.org.

On June 19, 2024, the College of American Pathologists released updates to the CAP Cancer Protocols. The release features content changes to 16 protocols.

Highlights of the Q2 updates include: 

  • Invasive Melanoma of The Skin: Excision, Re-Excision: pN Category staging correction and overall editing in conjunction with AJCC for improved clarity of classifications.
  • Breast Invasive Resection: All individual Residual Cancer Burden (RCB) reporting parameters are now optional and explanatory note updated to clarify use of “y” prefix and gross sampling for RCB Score reporting
  • Kidney Resection and Biopsy: WHO 5th edition update to content and explanatory notes
  • Vulva Resection: Separated “Margin Status for Paget Disease” elements from the “Margin Status for Precursor Lesions of Squamous Cell Carcinoma” question and semantic change to pT3 and pN0(i+) staging terminology
  • Bone & Soft Tissue Resection and Biopsy: Updates to content and explanatory notes, including WHO Histologic Types and addition of core and optional questions

All changes are outlined in the June 2024 Summary of Revisions.

If you have questions or concerns, please email cancerprotocols@cap.org.

On December 13, 2023, the College of American Pathologists released updates to the CAP Cancer Protocols. The release featured two new protocols, as well as content changes to 11 protocols.

Highlights of the Q4 updates include:  

  • Two NEW melanoma protocols: Invasive Melanoma, Excision (v1.0.0.0) and Invasive Melanoma, Biopsy (v1.0.0.0) 
  • Two existing melanoma cancer protocols were retired: Melanoma, Biopsy (v4.3.1.0) and Melanoma, Excision (v4.3.0.2) 
  • Colon, Resection protocol was updated to remove transanal disk procedure and add submucosal invasion for pT1 tumors 
  • Colon Biopsy protocol was updated to include transanal disk procedure
  • Six gastrointestinal NET cancer protocols updated to reflect WHO and AJCC content  
  • Two gynecologic cancer protocols updated to reflect AJCC and/or FIGO content 

All changes are outlined in the December 2023 Summary of Revisions.

If you have questions or concerns, please email cancerprotocols@cap.org.

On September 20, 2023, the College of American Pathologists released updates to the CAP Cancer Protocols. The release featured three new protocols, as well as content changes to 30 protocols.

Highlights of this release include:

  • Three new hematology cancer protocols including Precursor and Mature Lymphoid Malignancies, Myeloid and Mixed / Ambiguous Neoplasms, and Plasma Cell Malignancies. These new protocols reflect current WHO guidelines.
  • Four existing hematology cancer protocols will be retired: Bone Marrow, Hodgkin Lymphoma, Non-Hodgkin Lymphoma and Plasma Cell.
  • 12 pediatric protocols updated to reflect current WHO guidelines; these protocols will soon be required for CAP accreditation.
  • 13 genitourinary protocols updated to reflect current WHO guidelines.
  • Anus Local Excision updated to reflect AJCC version 9 content.

All changes are outlined in the September 2023 Summary of Revisions.

If you have questions or concerns, please email cancerprotocols@cap.org.

On June 21, 2023, the College of American Pathologists released updates to 6 CAP Cancer Protocols.

Highlights of this release include:

  • Five Head and Neck Cancer Protocols were revised to reflect the WHO 5th Edition (Blue Books) including updates to Histologic Types, Grades, and Explanatory Notes.
  • The Breast Invasive Resection protocol was revised to include conditional Residual Cancer Burden (RCB) reporting following neoadjuvant treatment.

All changes are outlined in the June 2023 Summary of Revisions.

If you have questions or concerns, please email cancerprotocols@cap.org.

The CAP released an accelerated update to the CAP Cancer Uterine Cervix Resection Protocol on April 5th, 2023. This update addresses an incorrect section header text for pTNM Classification to reflect use of AJCC 9th Version content.

The staging classifications themselves are not affected, as they were updated to the AJCC 9th Version in October 2020.

CAP Cancer Protocol users should refrain from using versions 5.1.0.0 and 4.003.001 of the CAP Cancer Protocol for Uterine Cervix Resection, as these versions are invalid.

All changes are outlined in the April 2023 Summary of Changes.

If you have questions or concerns, please email cancerprotocols@cap.org.

On March 22, 2023, the College of American Pathologists released updates to 10 CAP Cancer Protocols.

Highlights of content changes in this release include:

  • Thyroid protocol updated to reflect current WHO guidelines
  • Breast Biomarker and Breast Invasive Resection protocols now include notes for HER2neu Low Expression
  • Breast Invasive Biopsy has been updated to reflect the size of largest invasive focus in the limited biopsy sample
  • Gynecologic Biomarker has been updated to clarify content elements
  • Ovary protocol includes content clarification, updates to TNM modifiers, LVI visible text, and contains critical information updated in explanatory notes
  • Cervix Resection and Excision protocols also include content clarification, updates to LVI visible text, and TNM modifiers (Resection only)
  • Stomach Resection has changes to Histologic Grade Requirements
  • Adrenal Resection contains critical information updated in explanatory notes

All changes are outlined in the Summary of Revisions.

Cancer Reporting and Biomarker Reporting Protocols

Previous versions are available upon request at cancerprotocols@cap.org

Breast

Breast DCIS, ResectionCurrent Version
PDF (v4.4.0.0)
Word (v4.4.0.0)
June 2021
Previous Version
2020 (v4.3.0.2)
2019 (v4.3.0.1)
2019 (v4.3.0.0)
2019 (v4.2.0.0)
Breast DCIS, BiopsyCurrent Version
PDF (v1.0.1.0)
Word (v1.0.1.0)
June 2021
Previous Version
2020 (v1.0.0.1)
2019 (v1.0.0.0)
Breast Phyllodes TumorCurrent Version
PDF (v1.1.0.1)
Word (v1.1.0.1)
September 2022
Previous Version
2022 (v1.1.0.0)
2022 (v1.0.0.0)
Breast Invasive, ResectionCurrent Version
PDF (v4.10.0.0)
Word (v4.10.0.0)
June 2024
Previous Version
2023 (v4.9.0.1)
2023 (v4.9.0.0)
2023 (v4.8.1.0)
2022 (v4.8.0.0)
2022 (v4.7.0.1)
2022 (v4.7.0.0)
2022 (v4.6.0.0)
2021 (v4.5.0.1)
Breast Invasive, BiopsyCurrent Version
PDF (v1.2.0.0)
Word (v1.2.0.0)
March 2023
Previous Version
2022 (v1.1.1.2)
2021 (v1.1.1.1)
2021 (v1.1.1.0)
2020 (v1.1.0.0)
Breast Biomarker ReportingCurrent Version
PDF (v1.6.0.0)
Word (v1.6.0.0)
March 2025
Previous Version
2023 (v1.5.0.1)
2022 (v1.5.0.0)
2021 (v1.4.1.1)
2021 (v1.4.1.0)
2020 (v1.4.0.0)

Central Nervous System

Central Nervous SystemCurrent Version
PDF (v1.0.0.0)
Word (v1.0.0.0)
September 2022
Previous Version
2018 (v4.0.0.0)
RETIRED

Endocrine

Adrenal GlandCurrent Version
PDF (v4.3.1.0)
Word (v4.3.1.0)
March 2023
Previous Version
2022 (v4.3.0.0)
2021 (v4.2.1.0)
2021 (v4.2.0.0)
2020 (v4.1.0.0)
Appendix NETCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
December 2023
Previous Version
2021 (v4.1.0.0)
2020 (v4.0.0.2)
Colon NETCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
December 2023
Previous Version
2021 (v4.1.0.0)
2020 (v4.0.0.2)
Duodenum and Ampulla NETCurrent Version
PDF (v2.0.0.1)
Word (v2.0.0.1)
June 2024
Previous Version
2023 (v2.0.0.0)
2021 (v1.1.0.0)
2020 (v1.0.0.2)
Jejunum and Ileum NETCurrent Version
PDF (v2.0.0.0)
Word (v2.0.0.0)
December 2023
Previous Version
2021 (v1.1.0.0)
2020 (v1.0.0.1)
Pancreas (Endocrine)Current Version
PDF (v5.0.1.0)
Word (v5.0.1.0)
June 2024
Previous Version
2023 (v5.0.0.0)
2021 (v4.1.0.0)
2020 (v4.0.0.2)
Paraganglioma Pheochromocytoma *NEW*Current Version
PDF (v1.0.0.0)
Word (v1.0.0.0)
March 2025
 
Pituitary Neuroendocrine (PitNET) *NEW* Current Version
PDF (v1.0.0.0)
Word (v1.0.0.0)
March 2025
 
Stomach NETCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
December 2023
Previous Version
2021 (v4.1.0.0)
2020 (v4.0.0.2)
ThyroidCurrent Version
PDF (v4.4.0.0)
Word (v4.4.0.0)
March 2023
Previous Version
2022 (v4.3.0.0)
2020 (v4.2.0.0)
Thyroid Biomarker ReportingCurrent Version
PDF (v1.0.0.1)
Word (v1.0.0.1)
June 2016
Previous Version
2015 (v1.0.0.0)

Gastrointestinal

Ampulla of VaterCurrent Version
PDF (v4.2.0.1)
Word (v4.2.0.1)
November 2021
Previous Version
2021 (v4.2.0.0)
2020 (v4.1.0.0)
Anus, ExcisionCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
September 2023
Previous Version
2021 (v4.2.0.0)
2020 (v4.1.0.1)
2020 (v4.1.0.0)
Anus, ResectionCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
June 2022
Previous Version
2021 (v4.2.0.1)
2021 (v4.2.0.0)
2020 (v4.1.0.0)
AppendixCurrent Version
PDF (v5.1.0.0)
Word (v5.1.0.0)
December 2022
 
Previous Version
2022 (v5.0.0.0)
2021 (v4.2.0.0)
2020 (v4.1.0.0)
Colon and Rectum, BiopsyCurrent Version
PDF (v4.3.0.0)
Word (v4.3.0.0)
December 2023
Previous Version
2021 (v4.2.0.1)
2021 (v4.2.0.0)
2020 (v4.1.0.0)
Colon and Rectum, ResectionCurrent Version
PDF (v4.3.1.0)
Word (v4.3.1.0)
June 2024
Previous Version
2023 (v4.3.0.0)
2022 (v4.2.0.2)
2021 (v4.2.0.1)
2021 (v4.2.0.0)
Colon and Rectum Biomarker ReportingCurrent Version
PDF (v1.3.0.0)
Word (v1.3.0.0)
June 2021
Previous Version
2014 (v1.2.0.1)
Distal Extrahepatic Bile DuctsCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2021
Previous Version
2020 (v4.1.0.0)
EsophagusCurrent Version
PDF (v4.2.0.1)
Word (v4.2.0.1)
June 2022
Previous Version
2021 (v4.2.0.0)
2020 (v4.1.0.0)
GallbladderCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2021
Previous Version
2020 (v4.1.0.0)
GIST, BiopsyCurrent Version
PDF (v4.3.0.0)
Word (v4.3.0.0)
December 2022
Previous Version
2021 (v4.2.0.0)
2020 (v4.1.0.0)
GIST, ResectionCurrent Version
PDF (v4.3.0.0)
Word (v4.3.0.0)
December 2022
Previous Version
2021 (v4.2.0.0)
2020 (v4.1.0.0)
GIST Biomarker ReportingCurrent Version
PDF (v1.1.0.0)
Word (v1.1.0.0)
December 2022
Previous Version
2020 (v1.0.0.2)
2015 (v1.0.0.1)
2014 (v1.0.0.0)
Hepatocellular CarcinomaCurrent Version
PDF (v4.3.0.0)
Word (v4.3.0.0)
June 2022
Previous Version
2021 (v4.2.0.0)
2020 (v4.1.0.0)
Intrahepatic Bile DuctsCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2021
Previous Version
2020 (v4.1.0.0)
Pancreas (Exocrine)Current Version
PDF (v4.2.0.2)
Word (v4.2.0.2)
November 2021
Previous Version
2021 (v4.2.0.1)
2021 (v4.2.0.0)
2020 (v4.1.0.0)
Perihilar Bile DuctsCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2021
Previous Version
2020 (v4.1.0.0)
Small IntestineCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2021
Previous Version
2020 (v4.1.0.0)
StomachCurrent Version
PDF (v4.4.0.0)
Word (v4.4.0.0)
March 2023
Previous Version
2022 (v4.3.0.0)
2022 (v4.2.1.1)
2021 (v4.2.1.0)
2021 (v4.2.0.0)
2020 (v4.1.0.0)
Gastric HER2 Biomarker ReportingCurrent Version
PDF (v1.0.0.1)
Word (v1.0.0.1)
June 2017
Previous Version
2014 (v1.0.0.0)

Genitourinary

Kidney, BiopsyCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2024
Previous Version
2021 (v4.1.0.0)
2020 (v4.0.2.0)
Kidney, ResectionCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2024
Previous Version
2021 (v4.1.0.0)
2020 (v4.0.2.0)
PenisCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
September 2023
Previous Version
2021 (v4.1.0.0)
2017 (v4.0.1.0)
Prostate Needle Biopsy 
Case Level
Current Version
PDF (1.1.0.0)
Word (1.1.0.0)
September 2023
Previous Version
2021 (1.0.0.1)
2021 (1.0.0.0)
Prostate Needle Biopsy 
Specimen Level
Current Version
PDF (1.1.0.0)
Word (1.1.0.0)
September 2023
Previous Version
2021 (1.0.0.1)
2021 (1.0.0.0)
Prostate, ResectionCurrent Version
PDF (v4.3.0.0)
Word (v4.3.0.0)
September 2023
Previous Version
2021 (v4.2.0.1)
2021 (v4.2.0.0)
2020 (v4.1.0.1)
Prostate TURPCurrent Version
PDF(v4.2.0.0)
Word (v4.2.0.0)
September 2023
Previous Version
2021 (v4.1.0.0)
2020 (v4.0.5.0)
Testis OrchiectomyCurrent Version
PDF (v4.3.0.0)
Word (v4.3.0.0)
March 2025
Previous Version
2023 (v4.2.0.0)
2021 (v4.1.0.1)
2021 (v4.1.0.0)
Testis LymphadenectomyCurrent Version
PDF (v4.2.1.0)
Word (v4.2.1.0)
June 2024
Previous Version
2023 (v4.2.0.0)
2021 (v4.1.0.1)
2021 (v4.1.0.0)
Ureter, Renal Pelvis, BiopsyCurrent Version
PDF (v2.4.0.0)
Word (v2.4.0.0)
March 2025
Previous Version
2023 (v2.3.0.0)
2021 (v2.2.0.0)
Ureter, Renal Pelvis, ResectionCurrent Version
PDF (v2.4.0.0)
Word (v2.4.0.0)
March 2025
Previous Version
2023 (v2.3.0.0)
2021 (v2.2.0.0)
Urethra, BiopsyCurrent Version
PDF (v4.3.0.0)
Word (v4.3.0.0)
December 2024
Previous Version
2023 (v4.2.0.1)
2023 (v4.2.0.0)
Urethra, ResectionCurrent Version
PDF (v4.3.0.0)
Word (v4.3.0.0)
December 2024
Previous Version
2023 (v4.2.0.0)
2021 (v4.1.0.0)
Urinary Bladder, ResectionCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
September 2023
Previous Version
2021 (v4.1.0.0)
2020 (v4.0.2.0)
Urinary Bladder, BiopsyCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
September 2023
Previous Version
2021 (v4.1.0.0)
2020 (v4.0.2.0)

Gynecologic

Endometrium UterusCurrent Version
PDF (v5.1.0.0)
Word (v5.1.0.0)
December 2024
Previous Version
2023 (v5.0.0.0)
2022 (v4.4.0.0)
2022 (v4.3.0.0)
Gynecologic, BiomarkersCurrent Version
PDF (v1.2.0.0)
Word (v1.2.0.0)
December 2024
Previous Version
2023 (v1.1.0.0)
2022 (v1.0.0.0)
Ovary, Fallopian Tube, or PeritoneumCurrent Version
PDF (v1.5.0.0)
Word (v1.5.0.0)
June 2024
Previous Version
2023 (v1.4.0.0)
2022 (v1.3.0.2)
2021 (v1.3.0.1)
2021 (v1.3.0.0)
Trophoblastic TumorsCurrent Version
PDF (v4.1.0.1)
Word (v4.1.0.1)
November 2021
Previous Version
2021 (v4.1.0.0)
2017 (v4.0.0.0)
Uterine Cervix, ExcisionCurrent Version
PDF (v4.4.2.0)
Word (v4.4.2.0)
March 2023
Previous Version
2021 (v4.4.1.0)
2020 (v4.4.0.0)
2020 (v4.3.0.0)
Uterine Cervix, ResectionCurrent Version
PDF (v5.1.1.0)
Word (v5.1.1.0)
April 2023
Previous Version
2022 (v5.0.1.3)
2021 (v5.0.1.2)
2021 (v5.0.1.1)
2021 (v5.0.1.0)
2020 (v5.0.0.0)
2020 (v4.3.0.0)
Uterine SarcomaCurrent Version
PDF (v4.4.0.0)
Word (v4.4.0.0)
March 2022
Previous Version
2021 (v4.3.0.0)
2021 (v4.2.0.0)
2018 (v4.1.0.0)
Vagina, BiopsyCurrent Version
PDF (v4.3.0.0)
Word (v4.3.0.0)
June 2021
Previous Version
2019 (v4.2.0.0)
Vagina, ResectionCurrent Version
PDF (v4.3.0.1)
Word(v4.3.0.1)
November 2021
Previous Version
2021 (v4.3.0.0)
2020 (v4.2.0.1)
2019 (v4.2.0.0)
VulvaCurrent Version
PDF (v5.1.0.0)
Word (v5.1.0.0)
June 2024
Previous Version
2023 (v5.0.0.0)
2021 (v4.2.0.2)
2021 (v4.2.0.1)

Head and Neck

LarynxCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2023
Previous Version
2021 (v4.1.1.0)
2021 (v4.1.0.0)
Oral CavityCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2023
Previous Version
2021 (v4.1.1.0)
2021 (v4.1.0.1)
2021 (v4.1.0.0)
Major Salivary GlandsCurrent Version
PDF (v4.3.0.0)
Word (v4.3.0.0)
June 2023
Previous Version
2022 (v4.2.0.0)
2021 (v4.1.1.0)
2021 (v4.1.0.0)
Nasal Cavity and Paranasal SinusesCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2023
Previous Version
2021 (v4.1.1.0)
2021 (v4.1.0.0)
PharynxCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
December 2024
Previous Version
2023 (v4.3.0.0)
2023 (v4.2.0.0)
Head and Neck Biomarker ReportingCurrent Version
PDF (v2.2.0.0)
Word (v2.2.0.0)
September 2023
Previous Version
2021 (v2.0.0.1)
2021 (v2.0.0.0)
Cutaneous Squamous Cell CarcinomaCurrent Version
PDF (v1.1.0.0)
Word (v1.1.0.0)
December 2024
Previous Version
2022 (v1.0.0.1)
2022 (v1.0.0.0)

Hematologic

Precursor and Mature Lymphoid MalignanciesCurrent Version
PDF (v1.0.0.0)
Word (v1.0.0.0)
September 2023
Previous Version
 
Myeloid and Mixed / Ambiguous Lineage NeoplasmsCurrent Version
PDF (v1.1.0.0)
Word (v1.1.0.0)
June 2024
Previous Version
2023 (v1.0.0.0)
Plasma Cell MalignanciesCurrent Version
PDF (v1.0.0.0)
Word (v1.0.0.0)
September 2023
Previous Version
 

Ophthalmic

RetinoblastomaCurrent Version
PDF (v4.1.0.0)
Word (v4.1.0.0)
June 2021
Previous Version
2017 (v4.0.0.0)
Uveal MelanomaCurrent Version
PDF (v4.1.0.0)
Word (v4.1.0.0)
June 2021
Previous Version
2017 (v4.0.0.0)

Pediatric

Ewing, ResectionCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
September 2023
Previous Version
2022 (v4.1.1.1)
2022 (v4.1.1.0)
2021 (v4.1.0.0)
Ewing, BiopsyCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
September 2023
Previous Version
2022 (v4.1.1.1)
2022 (v4.1.1.0)
2021 (v4.1.0.0)
 
Germ Cell Tumor, ResectionCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
September 2023
Previous Version
2022 (v4.1.1.0)
2021 (v4.1.0.0)
2019 (v4.0.0.0)
Germ Cell Tumor, BiopsyCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
September 2023
Previous Version
2022 (v4.1.1.0)
2021 (v4.1.0.0)
Hepatoblastoma, ResectionCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
September 2023
Previous Version
2022 (v4.1.0.0)
2022 (v4.0.2.0)
2021 (v4.0.1.0)
Hepatoblastoma, BiopsyCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
September 2023
Previous Version
2022 (v4.1.0.0)
2022 (v4.0.1.0)
2021 (v4.0.0.1)
Neuroblastoma, ResectionCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
September 2023
Previous Version
2022 (v4.2.0.0)
2022 (v4.1.1.0)
2021 (v4.1.0.0)
Neuroblastoma, BiopsyCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
September 2023
Previous Version
2022 (v4.2.0.0)
2022 (v4.1.1.0)
2021 (v4.1.0.0)
 
Rhabdomyosarcoma, ResectionCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
September 2023
Previous Version
2022 (v4.1.1.1)
2022 (v4.1.1.0)
2021 (v4.1.0.0)
Rhabdomyosarcoma, BiopsyCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
September 2023
Previous Version
2022 (v4.1.1.1)
2022 (v4.1.1.0)
2021 (v4.1.0.0)
Wilms, ResectionCurrent Version
PDF (v4.4.0.0)
Word (v4.4.0.0)
March 2025
Previous Version
2023 (v4.3.0.1)
2022 (v4.3.0.0)
2022 (v4.2.0.0)
2021 (v4.1.0.0)
Wilms, BiopsyCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
September 2023
Previous Version
2022 (v4.1.0.0)
2022 (v4.0.1.0)
2021 (v4.0.0.1)
 

Skin

Invasive Melanoma of the Skin: BiopsyCurrent Version
PDF (v1.1.0.0)
Word (v1.1.0.0)
March 2025
Previous Version
2023 (v1.0.0.0)
Invasive Melanoma of the Skin: Excision, Re-ExcisionCurrent Version
PDF (v1.2.0.0)
Word (v1.2.0.0)
March 2025
Previous Version
2024 (v1.1.0.0)
2023 (v1.0.0.0)
Melanoma Biomarker ReportingCurrent Version
PDF (v1.0.0.2)
Word (v1.0.0.2)
July 2015
Previous Version
2015 (v1.0.0.1)
2015 (v1.0.0.0)
Merkel Cell CarcinomaCurrent Version
PDF (v4.1.0.0)
Word (v4.1.0.0)
June 2021
Previous Version
2017 (v4.0.0.1)

Thorax

Lung, ResectionCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
December 2024
Previous Version
2022 (v4.3.0.1)
2022 (v4.3.0.0)
Lung Biomarker ReportingCurrent Version
PDF (v2.0.1.1)
Word (v2.0.1.1)
September 2023
Previous Version
2021 (v2.0.1.0)
2021 (v2.0.0.0)
Diffuse Pleural MesotheliomaCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
December 2024
Previous Version
2021 (v4.1.0.0)
ThymusCurrent Version
PDF (v5.0.0.0)
Word (v5.0.0.0)
December 2024
Previous Version
2021 (v4.1.0.0)

Bone and Soft Tissue

Bone, BiopsyCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2024
Previous Version
2021 (v4.1.0.1)
2021 (v4.1.0.0)
2020 (v4.0.1.0)
Bone, ResectionCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2024
Previous Version
2021 (v4.1.0.1)
2021 (v4.1.0.0)
2020 (v4.0.1.0)
Soft Tissue, BiopsyCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2024
Previous Version
2021 (v4.1.0.0)
2020 (v4.0.2.0)
2019 (v4.0.1.1)
Soft Tissue, ResectionCurrent Version
PDF (v4.2.0.0)
Word (v4.2.0.0)
June 2024
Previous Version
2021 (v4.1.0.0)
2020 (v4.0.2.0)
2019 (v4.0.1.1)

General

DNA Mismatch Repair Biomarker ReportingCurrent Version
PDF (v1.0.0.2)
Word (v1.0.0.2)
June 2021
Previous Version
2018 (v1.0.0.0)
Generic Template, BiopsyCurrent Version
PDF (v1.0.1.0)
Word (v1.0.1.0)
June 2021
Previous Version
2019 (v1.0.0.0)
Generic Template, ResectionCurrent Version
PDF (v1.1.0.0)
Word (v1.1.0.0)
June 2021
Previous Version
2019 (v1.0.0.0)
General IHC Quantitative BiomarkersCurrent Version
PDF (1.1.0.1)
Word (1.1.0.1)
September 2023
Previous Version
2021 (1.1.0.0)
2021 (1.0.0.0)

CAP Cancer Protocol Usage Limitations and Copyright

© 2023 College of American Pathologists (CAP). All rights reserved.

The College of American Pathologists (CAP) does not permit reproduction of any substantial portion of these protocols without its written authorization. The CAP hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the CAP.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) Dictation from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) Copying from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a computerized system for items (1) and (2), provided that the protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from the CAP.

Any public dissemination of the original or modified protocols is prohibited without a written license from the CAP.

The Protocols include tumor staging data used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this information is the AJCC Cancer Staging System (2020).

The CAP developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the CAP recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the required data elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the CAP cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.

Back to the top

Please direct questions or comments regarding CAP Cancer Protocols to cancerprotocols@cap.org.